TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07420816: Phase II Randomized, Multicenter, Double-blind, Doubledummy, Parallel Clinical Trial to Evaluate the Efficacy and Safety of APSTZD in the Treatment of Insomnia Disorder

Sponsor: Apsen Farmaceutica S.A. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 222 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT07420816 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07420816 Rescue Dossier →